February 8, 2025 Week in Review: Trade Wars, Earnings, and Labor Data
February 4, 2025 AI Ventures Soar as Trade Tensions Heat Up – Key Weekly Highlights
Tesla's Shanghai Megapack Factory: A Catalyst for Future Growth
Nvidia: Seizing Long-Term Growth Amid Cost Challenges and AI Momentum
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025
January 1, 2025 Advanced Charting Tools For Traders
December 21, 2024 Why Is Trading Important?
Merck & Co. (MRK) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: February 16, 2025 (09:29)
Sector: HealthcareThe share price of Merck & Co., Inc. (MRK) now
Analysts predictions
Full report|
This Week
|
Bullish | Opinions: 2 (2/0/0) |
|
Previous Week
|
Neutral | Opinions: Na |
|
Two Weeks Ago
|
Bullish | Opinions: 2 (2/0/0) |
|
Three Weeks Ago
|
Neutral | Opinions: Na |
Are you interested in Merck & Co., Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Merck & Co. stock price in 2025, 2026, 2027. How much will one Merck & Co. share be worth in 2025 - 2027?
When should I take profit in Merck & Co. stock? When should I record a loss on Merck & Co. stock? What are analysts' forecasts for Merck & Co. stock? What is the future of Merck & Co. stock? We forecast Merck & Co. stock performance using neural networks based on historical data on Merck & Co. stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Merck & Co. stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Merck & Co. shares. This happens once a day.
Historical and forecast chart of Merck & Co. stock
The chart below shows the historical price of Merck & Co. stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Merck & Co. stock price can be found in the table below.
Long-term forecasts by years.
Merck & Co., Inc. Analysts predictions review
Merck's upcoming stock trend reflects a cautiously positive outlook. While the company faces near-term risks such as regulatory scrutiny on drug pricing and sector volatility, its strong R&D pipeline, strategic acquisitions, and robust cash generation provide long-term growth potential. Drugs like Keytruda continue to drive significant revenues, and the company's geographic diversification reduces risk exposure. Despite valuation concerns and heightened competition, Merck's operational efficiency, dividend payouts, and well-managed risk strategies enhance its appeal to income investors. The stock's resilience in a stable pharmaceutical sector further supports its positioning.
Merck Stock Under Pressure: Evaluating Risks and Opportunities
Merck's recent stock performance reflects several challenges, including heightened regulatory scrutiny that could weigh on its near-term outlook. Potential risks from stricter government policies on drug pricing, particularly in the U.S., remain a focal concern, as these measures could lead to margin compression and muted revenue growth for its blockbuster therapies.
Upcoming market conditions, especially within the pharmaceutical sector, indicate increased volatility driven by macroeconomic headwinds and sector rotation to defensive positions. The author highlights that investor sentiment may further weaken if macro data continues to erode, amplifying selling pressure on MRK shares.
Pipeline Strength and Competitive Landscape
Merck’s pipeline continues to show promise, with late-stage clinical trials for key drugs poised for FDA approvals, which could mitigate recent stock declines. Despite competitive pressures from both generic manufacturers and rival pharma firms, strategic acquisitions and innovative R&D initiatives underscore Merck's resilience in sustaining long-term revenue streams.
Valuation concerns linger, as the stock currently trades at higher multiples compared to its historical averages amid broader market weakness. However, the company’s strong balance sheet and consistent dividend payouts may still appeal to income-focused investors, offering a semblance of stability during market turbulence.
Merck's Growth Potential Bolstered by Strategic Hedging and Upgraded Forecast
Merck's adoption of option collars reflects a tactical approach aimed at minimizing downside risk while safeguarding upside potential. This strategy, highlighted by the author, not only signifies prudent financial management but also underscores the company's awareness of broader market volatility, a factor that could influence confidence among institutional investors.
Additionally, the upgrade to a 'Buy' rating signals growing optimism about Merck's growth trajectory amidst favorable drug pipelines and potential for revenue expansion. The critical emphasis on strong research and development (R&D) capabilities further underlines the company's ability to maintain a competitive edge, which could catalyze higher stock valuation.
Strategic Factors Driving Stock Performance
The author's argument also emphasized Merck's robust cash generation ability, which is vital for sustaining dividend payouts and funding future growth initiatives. This financial strength is likely to support the stock's attractiveness among income-focused investors while providing ample resources for strategic reinvestment.
The broader pharmaceutical sector's stable outlook adds another pillar of support to Merck's positioning. While macroeconomic conditions remain a variable, the expected resilience of healthcare demand serves as a shield, limiting downside risk for the stock price in the near term.
Merck's Undervalued Position: A Strategic Opportunity for Long-Term Growth
Merck's stock valuation appears to be heavily discounted despite the company's strong fundamentals. The author emphasizes the disconnect between Merck's earnings potential and its current market price, positioning the stock as an attractive investment opportunity. A combination of robust revenue streams and operational efficiency underscores the company's resilience in a competitive market.
Strong Catalysts Bolstering Outlook
The company’s pipeline of innovative drugs and treatments is a cornerstone of its growth prospects. According to the author, blockbuster drugs such as Keytruda continue to drive significant revenue, contributing to a stable outlook on future cash flows and supporting shareholder returns.
Merck’s geographic diversification reduces dependency on any single market, enhancing its ability to navigate global regulatory and economic challenges. This diversification further secures a competitive advantage, making the stock less vulnerable to region-specific risks.
Cost management and efficiency improvements have been cited as factors reinforcing Merck's profitability. By maintaining a disciplined approach to expenses while reinvesting in high-potential areas, Merck demonstrates a commitment to sustained margin expansion over the medium to long term.
Merck's focus on sustainable dividend growth and its positioning near 52-week lows make it an attractive consideration for income-focused investors. According to the author, this valuation level enhances the stock's appeal for long-term holders, balancing its defensive nature with robust cash flow generation to sustain payouts.
Key to Merck's growth narrative is its innovative pharmaceutical pipeline, with blockbuster drugs such as Keytruda driving strong earnings momentum. The author emphasizes that Keytruda's expanding applications in oncology provide a competitive advantage, buttressing Merck's long-term revenue trajectory.
Impact of Market Valuation and Pipeline Innovation on MRK
The company’s solid fundamentals, combined with a favorable risk-reward profile at its current valuation, present a compelling entry point for those seeking stability amid broader market volatility. The author underscores its relative outperformance in the healthcare sector, signaling Merck's resilience in uncertain economic conditions.
Finally, concerns about patent expirations and potential competitive pressure are managed well by Merck's strategic investments in R&D and acquisitions. These efforts, coupled with a diversified product portfolio, position the company to mitigate risks and sustain growth.
Merck's strong pipeline of innovative drugs and therapies is a critical driver of its long-term growth potential. The author highlights key advancements in oncology and vaccines, which are expected to generate significant revenue growth in the coming years and strengthen its competitive positioning in the pharmaceutical sector.
Expanding margins through a disciplined approach to cost management plays an essential role in the company's strategy. According to the author, operational efficiencies combined with pricing power in its key product categories provide Merck with a robust buffer against inflationary pressures.
Key Drivers and Investment Potential
Additionally, Merck's leadership in the immuno-oncology market is fortified by Keytruda, a cornerstone of its product portfolio and an industry leader in cancer treatments. The author's analysis suggests that sales momentum for Keytruda remains strong and should continue to anchor earnings reliability.
Lastly, Merck's shareholder-friendly policies, including steady dividend growth, add an attractive value proposition. The commitment to returning capital to shareholders signals confidence in free cash flow sustainability and enhances the stock's defensive appeal in uncertain market conditions.
Merck & Co., Inc. (MRK) boasts a notable 3.2% dividend yield coupled with a robust 9.3% five-year dividend growth rate. These figures underscore the company's capacity to deliver consistent shareholder returns while maintaining an aggressive dividend growth trajectory, making it an attractive option for income-focused investors.
Strong performance in Merck’s key therapeutic areas, particularly oncology and vaccines, reinforces its competitive positioning within the pharmaceutical industry. These segments, led by flagship products like Keytruda, continue to drive revenue growth, supporting the author's assertion of sustained profitability.
Pipeline Strength and Strategic Investments
The company's research and development pipeline remains a critical growth driver, as evidenced by significant investments in breakthrough therapies and acquisitions. These efforts position Merck for long-term innovation, potentially ensuring a steady flow of high-margin treatments to offset patent cliffs.
Global sales momentum further anchors Merck’s financial health, with emerging markets delivering incremental growth. This geographic diversification shields the business from domestic market fluctuations, aligning with the author’s claim of resilience across market cycles.
Finally, the relatively stable valuation metrics indicate that the current stock price offers a favorable entry point, particularly in the context of its revenue growth projections. This aligns with the author's recommendation to consider Merck a compelling buy opportunity in the near term.
Merck's robust growth trajectory is underpinned by its successful portfolio of blockbuster products, including its flagship oncology drug, Keytruda. The drug's expanding dominance in the cancer treatment market, coupled with its ability to maintain pricing power despite competitive pressures, serves as a key driver for consistent revenue growth and resilience against broader economic challenges.
Significant Catalysts Shaping Merck's Performance
The company’s pipeline strength is another critical factor, particularly its focus on developing innovative therapies in high-growth areas such as immunology and vaccines. According to the author, these advancements could fortify Merck’s market position in the coming years, mitigating risks of reliance on existing product lines.
Additionally, strategic acquisitions have positioned Merck to broaden its revenue base and leverage synergies in R&D and commercialization efforts. This approach demonstrates an effective use of capital and a commitment to sustaining long-term shareholder returns.
Finally, favorable regulatory milestones and increased global health spending indicate a supportive macro backdrop for pharmaceutical companies like Merck. These developments may enhance investor sentiment and provide upward momentum for the stock in the near term.
Merck's valuation has reached levels that suggest a significant discount compared to its historical average, attracting value-focused investors. The author emphasizes that this pricing reflects market concerns, especially regarding short-term headwinds, but also opens the door for long-term upside potential as these concerns are mitigated.
Growth drivers, particularly Merck's oncology portfolio led by Keytruda, remain strong and continue to underpin the company’s revenue streams. According to the author, this pipeline positions Merck as a leader in innovative therapies, reinforcing the resilience of its earnings even in uncertain macroeconomic conditions.
Pipeline and Strategic Optionality
Merck’s R&D investments and strategic acquisitions are critical factors in maintaining its competitive edge. The author argues that the company’s focus on pipeline development and potential new blockbuster drugs could lead to meaningful value creation over time, serving as a catalyst for stock appreciation.
Short-term risks, including competition and patent cliffs, are a challenge but appear to be priced into the current valuation. The author notes that these risks, while real, are manageable and likely to dissipate as the company's growth drivers continue to offset the potential downside over the medium to long term.
Merck & Co is an international pharmaceutical company. Develops, manufactures and distributes vaccines and medicines. Also publishes non-commercial medical journals, reference books. In all countries except the United States and Canada, the company’s products are sold under the Merck Sharp & Dohme brand.
The company operates in 120 countries: North America, Latin America, Europe, Africa, Asia and the Middle East. Merck & Co employs 76 thousand people. For 23 years, Fortune magazine has included the company in the Fortune Global 500 – the rating of the largest corporations in the world. In 2017, Merck was ranked 246th.
The history of the company began in 1668 when Jacob Merck bought a pharmacy in Germany. 150 years later, Jacob’s great-grandson took over the family business and began mass production of drugs. At the beginning of the 20th century, Merck & Co was considered the largest producer of alkaloids: morphine, codeine and cocaine.
Merck & Co. daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Feb 18 | 82.66 | 82.11 | 83.27 | 1.42 |
| Feb 19 | 82.71 | 82.45 | 83.12 | 0.81 |
| Feb 20 | 82.61 | 82.29 | 83.11 | 0.99 |
| Feb 21 | 82.92 | 82.48 | 83.16 | 0.81 |
| Feb 22 | 83.05 | 82.66 | 83.71 | 1.28 |
| Feb 23 | 82.76 | 82.50 | 83.03 | 0.64 |
| Feb 24 | 82.58 | 82.20 | 82.88 | 0.82 |
| Feb 25 | 82.20 | 81.60 | 82.84 | 1.51 |
| Feb 26 | 82.80 | 82.32 | 83.02 | 0.84 |
| Feb 27 | 82.87 | 82.31 | 83.44 | 1.38 |
| Feb 28 | 82.61 | 82.17 | 83.05 | 1.08 |
| Mar 01 | 82.23 | 81.65 | 82.79 | 1.40 |
| Mar 02 | 82.00 | 81.60 | 82.31 | 0.86 |
| Mar 03 | 82.08 | 81.60 | 82.59 | 1.21 |
| Mar 04 | 82.39 | 81.97 | 82.91 | 1.15 |
| Mar 05 | 83.11 | 82.49 | 83.40 | 1.10 |
| Mar 06 | 82.93 | 82.62 | 83.42 | 0.97 |
| Mar 07 | 83.08 | 82.56 | 83.35 | 0.97 |
| Mar 08 | 82.47 | 81.86 | 82.94 | 1.33 |
| Mar 09 | 81.92 | 81.50 | 82.35 | 1.04 |
| Mar 10 | 82.08 | 81.91 | 82.73 | 1.00 |
| Mar 11 | 81.45 | 80.96 | 82.08 | 1.38 |
| Mar 12 | 81.71 | 81.25 | 81.93 | 0.83 |
| Mar 13 | 81.77 | 81.33 | 82.39 | 1.31 |
| Mar 14 | 82.18 | 81.92 | 82.77 | 1.04 |
| Mar 15 | 82.54 | 82.06 | 82.93 | 1.06 |
| Mar 16 | 81.88 | 81.69 | 82.41 | 0.87 |
| Mar 17 | 81.77 | 81.49 | 81.94 | 0.55 |
| Mar 18 | 81.28 | 81.01 | 81.84 | 1.02 |
| Mar 19 | 81.42 | 81.00 | 81.68 | 0.84 |
Merck & Co. Daily Price Targets
Merck & Co. Stock Forecast 02-18-2025.
Forecast target price for 02-18-2025: $82.66.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 1.400%.
Pessimistic target level: 82.11
Optimistic target level: 83.27
Merck & Co. Stock Forecast 02-19-2025.
Forecast target price for 02-19-2025: $82.71.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 0.806%.
Pessimistic target level: 82.45
Optimistic target level: 83.12
Merck & Co. Stock Forecast 02-20-2025.
Forecast target price for 02-20-2025: $82.61.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 0.984%.
Pessimistic target level: 82.29
Optimistic target level: 83.11
Merck & Co. Stock Forecast 02-21-2025.
Forecast target price for 02-21-2025: $82.92.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 0.808%.
Pessimistic target level: 82.48
Optimistic target level: 83.16
Merck & Co. Stock Forecast 02-22-2025.
Forecast target price for 02-22-2025: $83.05.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 1.260%.
Pessimistic target level: 82.66
Optimistic target level: 83.71
Merck & Co. Stock Forecast 02-23-2025.
Forecast target price for 02-23-2025: $82.76.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 0.638%.
Pessimistic target level: 82.50
Optimistic target level: 83.03
MRK (MRK) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Mar. | 85.91 | 84.36 | 86.87 | 2.89 |
| Apr. | 88.11 | 86.55 | 88.88 | 2.62 |
| May. | 88.03 | 85.46 | 89.90 | 4.94 |
| Jun. | 85.08 | 84.19 | 87.19 | 3.43 |
| Jul. | 86.34 | 84.92 | 87.13 | 2.54 |
| Aug. | 86.68 | 84.36 | 87.79 | 3.91 |
| Sep. | 89.80 | 87.61 | 91.92 | 4.69 |
| Oct. | 90.81 | 88.56 | 92.66 | 4.43 |
| Nov. | 92.48 | 91.70 | 93.26 | 1.67 |
| Dec. | 89.26 | 87.94 | 90.72 | 3.07 |
Merck & Co. forecast for this year
Merck & Co. Stock Prediction for Mar 2025
An uptrend is forecast for this month with an optimal target price of $85.9058. Pessimistic: $84.36. Optimistic: $86.87
Merck & Co. Stock Prediction for Apr 2025
An uptrend is forecast for this month with an optimal target price of $88.105. Pessimistic: $86.55. Optimistic: $88.88
Merck & Co. Stock Prediction for May 2025
An downtrend is forecast for this month with an optimal target price of $88.0345. Pessimistic: $85.46. Optimistic: $89.90
Merck & Co. Stock Prediction for Jun 2025
An downtrend is forecast for this month with an optimal target price of $85.0765. Pessimistic: $84.19. Optimistic: $87.19
Merck & Co. Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $86.3357. Pessimistic: $84.92. Optimistic: $87.13
Merck & Co. Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $86.681. Pessimistic: $84.36. Optimistic: $87.79
Merck & Co. Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $89.8015. Pessimistic: $87.61. Optimistic: $91.92
Merck & Co. Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $90.8073. Pessimistic: $88.56. Optimistic: $92.66
Merck & Co. Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $92.4782. Pessimistic: $91.70. Optimistic: $93.26
Merck & Co. Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $89.2599. Pessimistic: $87.94. Optimistic: $90.72
Merck & Co. (MRK) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 90.51 | 89.79 | 93.12 | 3.58 |
| Feb | 90.40 | 88.12 | 92.61 | 4.84 |
| Mar | 93.00 | 92.26 | 94.60 | 2.48 |
| Apr | 94.27 | 93.48 | 95.82 | 2.44 |
| May | 93.70 | 92.20 | 96.51 | 4.47 |
| Jun | 91.83 | 89.99 | 92.97 | 3.20 |
| Jul | 90.65 | 89.82 | 92.68 | 3.09 |
| Aug | 93.74 | 92.91 | 95.72 | 2.94 |
| Sep | 97.19 | 95.40 | 100.02 | 4.63 |
| Oct | 95.71 | 93.11 | 98.66 | 5.63 |
| Nov | 97.36 | 96.46 | 98.64 | 2.21 |
| Dec | 96.58 | 95.11 | 98.20 | 3.15 |
Merck & Co. (MRK) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 95.92 | 94.19 | 97.45 | 3.35 |
| Feb | 98.14 | 95.28 | 99.56 | 4.30 |
| Mar | 98.26 | 95.79 | 99.25 | 3.49 |
| Apr | 100.11 | 97.91 | 102.03 | 4.04 |
| May | 102.59 | 101.28 | 104.60 | 3.18 |
| Jun | 103.54 | 101.34 | 104.90 | 3.40 |
| Jul | 103.21 | 101.02 | 105.23 | 4.00 |
| Aug | 100.69 | 98.79 | 101.49 | 2.66 |
| Sep | 98.79 | 97.85 | 100.06 | 2.21 |
| Oct | 97.61 | 95.11 | 100.54 | 5.40 |
| Nov | 101.08 | 98.50 | 102.78 | 4.17 |
| Dec | 100.23 | 97.71 | 101.60 | 3.83 |
Merck & Co. information and performance
2000 GALLOPING HILL ROAD, KENILWORTH, NJ, US
Market capitalization of the Merck & Co., Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of MRK shares in the company outstanding by the market price of one share.
EBITDA of Merck & Co. is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Merck & Co. (MRK) stock dividend
Merck & Co. last paid dividends on 03/17/2025. The next scheduled payment will be on 04/07/2025. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Merck & Co. Stock)
Should I Buy Merck & Co. Shares in 2025 year?
Does Merck & Co. pay dividends?
Which economic sector do Merck & Co.'s shares belong to?
Which other securities belong to the same sector as Merck & Co.'s shares?
